Clinical Trial Update: Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis [Phase 2]

View source ↗

Summary

A Phase 2 open-label trial of oral CEP-701 (lestaurtinib) in Polycythemia Vera and Essential Thrombocythemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocytosis
• Polycythemia Vera

Drugs mentioned

• CEP-701 (Lestaurtinib) (lestaurtinib)

Snippet

Sponsor: Cephalon | Conditions: Polycythemia Vera, Essential Thrombocytosis | Phase 2 | Status: COMPLETED